CTRI/2020/03/023844尚未招募未知
Pirfenidone as an antifibrotic agent in the treatment of oral submucous fibrosis-A Pilot study
Dr Akshaya S R0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Female and male with positive history of areca nut chewing in any form
- •2. Patients with clinically diagnosed Oral submucous fibrosis
- •3. Patients those who are willing to take part in the study
排除标准
- •1. Patient with systemic disorders such as uncontrolled diabetes, Systemic hypertension, cardiac illness, liver disease, bleeding disorder, gastrointestinal disorder and renal disease.
- •2. Patients with TMJ disorders and other forms of trismus are excluded from the study
- •3. Those who had received previous treatment were excluded from the study
- •4. Patients who is under Fluvoxamine and ciprofloxacin are not included in the study
- •5.Patients who are smoking are not included in the study
- •6. Patients not willing to give up addiction habits of Gutka, Pan-Masala, tobacco, etc
研究者
相似试验
进行中（未招募）
4 期
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaNovel Coronavirus-induced Lung FibrosisNCT04856111Post Graduate Institute of Medical Education and Research, Chandigarh48
已完成
2 期
Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT02136992Shanghai Pulmonary Hospital, Shanghai, China160
已完成
2 期
Pirfenidone, an Antifibrotic and Antiinflammatory DrugFibrosisHepatitis C ChronicNCT02161952University of Guadalajara150
已完成
2 期
Pirfenidone and Advanced Liver Fibrosis.Liver FibrosisChronic Liver DiseaseNCT04099407Grupo Mexicano para el Estudios de las Enfermedades Hepaticas122
尚未招募
Unknown
sefulness of a new medicine -pirfenidone in oral fibrosis due to Arecanut and tobacco useCTRI/2023/04/051723Indian Council of Medical Research